CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today a number of changes in its organisation structure and its senior executive group, within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years.

Following a period of outstanding leadership, Mr. Peter Turner will become Chief Operating Officer, CSL Group effective 1 January 2010 and will join the CSL Board as an Executive Director effective immediately, while continuing as President of CSL Behring, Mr. Turner will continue to be based in King of Prussia, Pennsylvania, USA.

Download the full release:
PDF icon

CHANGES TO CSL SENIOR EXECUTIVE GROUP

(0.12Mb)

For further information, please contact:

	Mark Dehring Head of Investor Relations CSL Limited Telephone: +613 9389 2818 Email: mark.dehring@csl.com.au

	Dr Rachel David Director, Public Affairs CSL Limited Telephone: +613 9389 1821 Email: rachel.david@csl.com.au

Privacy | Terms of Use | Employees | Webmaster